The Latest Breaking News from Pfizer

Recent banking turmoil and rising interest rates have weighed heavily on investors’ sentiment lately. However, weak economic data signaling slowing growth could result in relatively easy monetary policies in the second half of 2023. Given the macroeconomic backdrop, investors could consider adding fundamentally sound low P/E stocks Pfizer (PFE), Chevron…

The JCVI has advised that clinically vulnerable children aged six months to four years should be offered the vaccincation.

Care home residents will be first to receive spring top-up jab as infections in England hit 2023 high

Around five million UK residents are eligible for the booster until the end of June

Millions of people will be sent their initial invitations through the NHS app, where they can also book their appointment.

Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out.

A vaccine for the potentially deadly respiratory syncytial virus (RSV) is being assessed by the TGA for use by people aged over 60.

Thanks to onerous regulations, life-saving drugs are more expensive and harder to get.

Sally Susman is the author of "Breaking Through: Communicating to Open Minds, Move Hearts, and Change the World."